Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Dec. 23, 2024
Ductal
carcinoma
in
situ
(DCIS),
a
noninvasive
breast
cancer,
rarely
metastasises
to
distant
locations.
When
the
initial
lesion
is
stable,
bone
marrow
metastasis
(BMM)
and
necrosis
(BMN)
are
even
less
common.
Here,
we
report
case
of
47-year-old
female
patient
who
underwent
localized
surgery
radiotherapy
for
right-sided
DCIS.
The
also
had
mutation
cancer
susceptibility
gene
1
(
BRCA1
,
OMIM:
113705)
tested
positive
progesterone
estrogen
receptors.
After
11
years
disease-free
survival,
developed
severe
thrombocytopenia,
anemia,
fever,
malaise,
generalized
multifocal
pain,
irregular
vaginal
bleeding.
A
nodule
was
later
found
right
axilla,
postoperative
biopsy
revealed
tumor
cells
from
breast.
three
biopsies,
Positron
Emission
Tomography,
18
F-fluorodeoxyglucose,
positron
emission
tomography,
computed
tomography
F-FDG
PET/CT)
scans,
other
examinations,
she
finally
diagnosed
with
BMM
BMN
(stable
primary
without
metastasis).
Despite
symptomatic
supportive
treatment,
ultimately
died
rapidly
as
her
condition
deteriorated.
In
this
case,
explored
possible
mechanisms
DCIS
by
reviewing
literature
related
discussing
heterogeneous
clinical
presentation
pathologic
phenotype.
diagnostic
therapeutic
course
extremely
challenging.
This
suggests
clinicians
that
regular
checkups
monitoring
necessary,
if
rate
low.
Cancer Immunology Immunotherapy,
Journal Year:
2025,
Volume and Issue:
74(4)
Published: Feb. 25, 2025
Cancer
cells
grow
and
survive
in
the
tumor
microenvironment,
which
is
a
complicated
process.
As
key
part
of
how
colorectal
cancer
(CRC)
progresses,
tumor-associated
macrophages
(TAMs)
exhibit
double
role.
Through
angiogenesis,
this
TAM
can
promote
growth
cancers.
Although
being
able
to
modify
adjust
immune
great
advantage,
these
also
anti-cancer
properties
including
direct
killing
cells,
presenting
antigens,
aiding
T
cell-mediated
responses.
The
delicate
regulatory
mechanisms
between
system
tumors
are
composed
complex
network
pathways
regulated
by
several
factors
hypoxia,
metabolic
reprogramming,
cytokine/chemokine
signaling,
cell
interactions.
Decoding
figuring
out
systems
become
significant
building
targeted
treatment
programs.
Targeting
TAMs
CRC
involves
disrupting
chemokine
signaling
or
adhesion
molecules,
reprogramming
them
an
anti-tumor
phenotype
using
TLR
agonists,
CD40
modulation,
selectively
removing
subsets
that
growth.
Multi-drug
resistance,
absence
accurate
biomarker,
drug
non-specificity
major
problems.
Combining
macrophage-targeted
therapies
with
chemotherapy
immunotherapy
may
revolutionize
treatment.
Macrophage
studies
will
advance
new
technology
multi-omics
methodologies
help
us
understand
build
specific
efficient
treatments.
Breast Cancer Targets and Therapy,
Journal Year:
2023,
Volume and Issue:
Volume 15, P. 525 - 540
Published: July 1, 2023
Luminal
breast
cancers
are
hormone
receptor
(estrogen
and/or
progesterone)
positive
that
further
divided
into
HER2-negative
luminal
A
and
HER2-positive
B
subtypes.
According
to
currently
accepted
convention,
they
represent
the
most
common
subtypes
of
cancer,
accounting
for
approximately
70%
cases.
Biomarkers
play
a
critical
role
in
functional
characterization,
prognostication,
therapeutic
prediction,
rendering
them
indispensable
clinical
management
invasive
cancer.
Traditional
biomarkers
include
clinicopathological
parameters,
which
increasingly
extended
by
genetic
other
molecular
markers,
enabling
comprehensive
characterization
patients
with
Liquid
biopsies
capturing
analyzing
circulating
tumor
cells
(CTCs)
DNA
(ctDNA)
emerging
technologies
envision
personalized
through
precision
oncology.
This
article
reviews
key
cancer
ongoing
developments.
Nanomaterials,
Journal Year:
2024,
Volume and Issue:
14(17), P. 1424 - 1424
Published: Aug. 31, 2024
The
increasing
incidence
of
breast
cancers
(BCs)
in
the
world
population
and
their
complexity
high
metastatic
ability
are
serious
concerns
for
healthcare
systems.
Despite
significant
progress
medicine
made
recent
decades,
efficient
treatment
invasive
still
remains
challenging.
Chemotherapy,
a
fundamental
systemic
method,
is
burdened
with
severe
adverse
effects,
efficacy
limited
by
resistance
development
risk
disease
recurrence.
Also,
current
diagnostic
methods
have
certain
drawbacks,
attracting
attention
to
idea
developing
novel,
more
sensitive
detection
therapeutic
modalities.
It
seems
solution
these
issues
can
be
provided
nanotechnology.
Particularly,
quantum
dots
(QDs)
been
extensively
evaluated
as
potential
targeted
drug
delivery
vehicles
and,
simultaneously,
sensing
bioimaging
probes.
These
fluorescent
nanoparticles
offer
unlimited
possibilities
surface
modifications,
allowing
attachment
biomolecules,
such
antibodies
or
proteins,
molecules,
among
others.
In
this
work,
we
discuss
applicability
QDs
cancer
diagnostics
light
knowledge.
We
begin
introducing
molecular
histopathological
features
BCs,
standard
regimens,
methods.
Further,
QDs,
along
uptake,
biodistribution
patterns,
cytotoxicity,
described.
Based
on
reports
published
years,
present
research
possible
QD
use
improving
BC
chemotherapeutic
photosensitizing
agents,
stages
development.
also
address
limitations
open
questions
regarding
topic.
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(33), P. 23744 - 23771
Published: Jan. 1, 2024
Introduction:
Pharmacotherapeutic
targets
for
breast
cancer
include
the
estrogen
receptor
(ER),
progesterone
(PR),
and
human
epidermal
growth
factor
(EGFR).
Inhibitors
of
these
receptors
could
be
interesting
therapeutic
candidates
treatment
management
(BC).
Aim:
This
study
used
GC-MS
HPLC
to
identify
bioactive
compounds
in
Pleurotus
ostreatus
(P.
ostreatus)
extracts
applied
silico
methods
potent
EGFR,
ER,
PR
inhibitors
from
as
potential
drug
candidates.
Method:
were
chemicals
P.
aqueous
(PO-A),
methanol
(PO-M),
ethanol
(PO-E),
chloroform
(PO-C),
n-hexane
(PO-H).
The
PR,
EGFR
model
optimization
molecular
docking
compounds/control
binding
pocket
simulated
using
AutoDock
Vina
PyRx.
drug-likeness,
pharmacokinetic,
pharmacodynamic
features
prospective
leads
all
anticipated.
Result:
results
indicated
existence
29
PO-A,
36
PO-M
PO-E,
42
PO-C,
22
PO-H
extracts.
With
only
o-tolylamino-acetic
acid
(4-nitro-benzylidene)-hydrazide
(-7.5
kcal
mol-1)
ethanolic
extract
bind
receptor.
on
other
hand,
identified
several
with
higher
affinities
than
control.
Ergotaman-3',6',18-trione
(-8.1
mol-1),
5,10-diethoxy-2,3,7,8-tetrahydro-1H,6H-dipyrrolo[1,2-a:1',2'-d]pyrazine
(-7.8
extract;
(-8.4
had
better
affinity
compared
(-7.7
mol-1).
Likewise,
ergotaman-3',6',18-trione
(-9.7
phenol,
2,4-bis(1,1-dimethyl
ethyl)
(-8.2
control,
gefitinib
(-7.9
regards
EGFR.
None
or
outperformed
control
any
proteins.
Phenols
flavonoids
such
quercetin,
luteolin,
rutin,
chrysin,
apigenin,
ellagic
acid,
naringenin
their
Conclusion:
class
phenols
lead
molecules
due
ability
strongly
proteins'
receptors.
These
showed
promising
drug-like
properties;
they
safe
new
creating
anticancer
medicines.
Cell Death and Disease,
Journal Year:
2024,
Volume and Issue:
15(7)
Published: July 30, 2024
Abstract
Breast
cancer
remains
a
significant
global
health
challenge,
and
its
mechanisms
of
progression
metastasis
are
still
not
fully
understood.
In
this
study,
analysis
TCGA
GEO
datasets
revealed
increase
in
CCT2
expression
breast
tissues,
which
was
associated
with
poor
prognosis
patients.
Functional
that
promoted
growth
through
activation
the
JAK2/STAT3
signaling
pathway.
Additionally,
E3
ubiquitin
ligase
Trim21
facilitated
ubiquitination
degradation,
significantly
reversing
protumor
effects
CCT2.
Most
interestingly,
we
discovered
exosomal
derived
from
cells
suppressed
proinflammatory
cytokine
secretion
CD4
+
T
cell.
Mechanistically,
constrained
Ca
2+
-NFAT1
signaling,
thereby
reducing
CD40L
on
These
findings
highlight
upregulation
as
potential
driver
immune
evasion.
Our
study
provides
new
insights
into
molecular
underlying
progression,
suggesting
is
promising
therapeutic
target
prognostic
predictor
for
cancer.
Journal of Cellular and Molecular Medicine,
Journal Year:
2024,
Volume and Issue:
28(15)
Published: Aug. 1, 2024
Abstract
Breast
cancer
(BC)
is
the
most
commonly
diagnosed
in
women
globally.
Natural
killer
(NK)
cells
play
a
vital
role
tumour
immunosurveillance.
This
study
aimed
to
establish
prognostic
model
using
NK
cell‐related
genes
(NKRGs)
by
integrating
single‐cell
transcriptomic
data
with
machine
learning.
We
identified
44
significantly
expressed
NKRGs
involved
cytokine
and
T
functions.
Using
101
learning
algorithms,
Lasso
+
RSF
showed
highest
predictive
accuracy
nine
key
NKRGs.
explored
cell‐to‐cell
communication
CellChat,
assessed
immune‐related
pathways
microenvironment
gene
set
variation
analysis
ssGSEA,
observed
immune
components
HE
staining.
Additionally,
drug
activity
predictions
potential
therapies,
expression
validation
through
immunohistochemistry
RNA‐seq
confirmed
clinical
applicability
of
The
nomogram
high
concordance
between
predicted
actual
survival,
linking
higher
purity
risk
scores
reduced
score.
NKRG‐based
offers
novel
approach
for
assessment
personalized
treatment
BC,
enhancing
precision
medicine.
Cancer Biomarkers,
Journal Year:
2025,
Volume and Issue:
42(3)
Published: March 1, 2025
Breast
cancer,
the
most
common
cancer
in
women,
is
characterized
by
cell
cycle
dysregulation
and
chromosome
segregation
errors,
leading
to
mitotic
catastrophe
genomic
instability.
Understanding
these
molecular
mechanisms
crucial
for
better
diagnosis
treatment.
We
used
databases
like
TIMER
2.0,
UALCAN,
Oncomine
determine
differential
expression
of
Budding
uninhibited
benzimidazole
1
(BUB1)
normal
pan-cancer
tissues.
we
also
Kaplan-Meier
Plotter
database
analyze
gene
associations
with
survival
outcomes,
bc-GenExMiner
v5.0
BUB1
histological
subtypes,
ctcRbase
miR-TV
identify
microRNAs
associated
breast
cancer.
Our
data
show
that
overexpressed
tumors,
metastatic
tissues,
circulating
tumor
cells,
shorter
overall
survival,
disease-free
relapse-free
compared
low-expression
patients.
strongly
correlated
E2F1/E2F8
expression,
suggesting
a
potential
regulatory
relationship
between
genes.
The
study
revealed
negative
correlation
target
miRNA
miR-495-3p
indicating
was
infiltration
CD4+
T
helper
2
(Th2)
subtypes
need
further
research.
Advanced NanoBiomed Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 8, 2025
The
dissemination
of
primary
solid
tumor
cells
to
distant
organs,
termed
metastasis,
is
a
major
cause
cancer‐related
deaths.
Circulating
(CTCs),
which
can
exist
as
individual
or
multicellular
clusters,
travel
through
the
bloodstream.
Their
isolation
from
liquid
biopsy
samples
increasingly
recognized
valuable
tool
for
diagnosis,
prognosis,
and
treatment
guidance
cancer
patients.
Current
methods
typically
rely
on
biomarkers
like
epithelial
cell
adhesion
molecule
(EpCAM)
utilize
technologies
such
magnetic
beads
microfluidic
chips.
However,
these
face
limitations
due
heterogeneity.
Furthermore,
that
transfer
into
CTCs
often
undergo
epithelial‐to‐mesenchymal
transition,
gaining
invasive
characteristics
while
losing
markers.
As
result,
are
difficult
detect
using
EpCAM‐based
methods.
Label‐free
microscale
tackle
biomarker‐based
by
leveraging
distinctive
physical
properties
CTCs,
their
size,
electrical
charge,
viscoelasticity,
deformability
contrast
them
normal
blood
cells.
This
review
evaluates
label‐free
methods,
including
deterministic
lateral
displacement,
microfiltration,
acoustophoresis,
dielectrophoresis,
whether
they
offer
deeper
insight
heterogeneity
dynamics
progression
treatment.
Additionally,
it
highlights
automated
platforms
high‐throughput
CTC
analysis.